Regenxbio Inc

NASDAQ:RGNXUnited States

Jun 24, 2024

Show headlines and story abstract

• Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial, from 11:58AM ET on Monday Jun 24, 2024 by MT Newswires

  11:58AM ET on Monday Jun 24, 2024 by MT Newswires
  Companies Mentioned: RGNX
  11:58 AM EDT, 06/24/2024 (MT Newswires) -- Regenxbio (RGNX) said Monday that it started the enrollment of a new group of patients aged 1 year to 3 years old for the phase 1/2 trial of RGX-202 in boys with Duchenne muscular dystrophy. The company sai...

• REGENXBIO Announces Expansion of AFFINITY DUCHENNE(R) Trial to Include a New Cohort of Younger Patients, from 7:05AM ET on Monday Jun 24, 2024 by PR Newswire

  7:05AM ET on Monday Jun 24, 2024 by PR Newswire
  Companies Mentioned: RGNX

  -- Company to begin enrollment ofpatients aged 1-3 years

  -- Expects data from younger cohort to be part of pivotal plans and BLA filing for broad label

  -- End-of-Phase II meeting with FDA scheduled for late July to finalize pivotalprogram design

• REGENXBIO Announces Expansion of AFFINITY DUCHENNE(R) Trial to Include a New Cohort of Younger Patients, from 7:05AM ET on Monday Jun 24, 2024 by Dow Jones

  7:05AM ET on Monday Jun 24, 2024 by Dow Jones
  Companies Mentioned: RGNX
  
  maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2023, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (SEC) and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.